1. Local delivery of alendronate eluting chitosan scaffold can effectively increase osteoblast functions and inhibit osteoclast differentiation
   Sung Eun Kim et al, 2012, J Mater Sci: Mater Med CrossRef
2. The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells
   Y. Açil et al, 2012, Journal of Cranio-Maxillofacial Surgery CrossRef
3. Synthesis and Biological Evaluation of New Bisphosphonate–Dextran Conjugates Targeting Breast Primary Tumor
   Evelyne Migianu-Griffoni et al, 2014, Bioconjugate Chem. CrossRef
4. Bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer
   Robin A. Nadar et al, 2017, Adv. Healthcare Mater. CrossRef
5. Bisphosphonate-modified biomaterials for drug delivery and bone tissue engineering
   Dmitri A Ossipov, 2015, Expert Opinion on Drug Delivery CrossRef
6. Application of accelerator mass spectrometry to macromolecules: preclinical pharmacokinetic studies on a polybisphosphonate
   Mehran Salehpour et al, 2011, Rapid Commun. Mass Spectrom. CrossRef
7. The effects of functionalized titanium with alendronate and bone morphogenic protein-2 for improving osteoblast activity
   Sung Eun Kim et al, 2013, Tissue Eng Regen Med CrossRef
8. Osteoblast migration into type I collagen gel and differentiation to osteocyte-like cells within a self-produced mineralized matrix: A novel system for analyzing differentiation from osteoblast to osteocyte
   Kazuyoshi Uchihashi et al, 2013, Bone CrossRef
9. Development of Bone Targeting Drugs
   Molly Stapleton et al, 2017, IJMS CrossRef
10. Bisphosphonate conjugation for bone specific drug targeting
    Kristen B. Farrell et al, 2018, Bone Reports CrossRef
11. Targeting anti-cancer agents to bone using bisphosphonates
    Lianping Xing et al, 2020, Bone CrossRef
12. Nanomedicine for the Treatment of Advanced Prostate Cancer
    Sonia Vicente‐Ruiz et al, 2020, Adv. Therap. CrossRef
13. Current World Literature
    , 2011 CrossRef
14. Cancer bone metastases and nanotechnology-based treatment strategies
    Zhaofeng Li et al, 2022, Expert Opinion on Drug Delivery CrossRef
15. Research progress of bone-targeted drug delivery system on metastatic bone tumors
    Beibei Hu et al, 2022, Journal of Controlled Release CrossRef
16. A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer (CRPC) and skeletal metastases
    C. Thellenberg-Karlsson et al, 2022, European Journal of Cancer CrossRef
17. The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages
    Petra Henning et al, 2024, Invest New Drugs CrossRef